Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
677 studies found for:    Open Studies | "Carcinoid Tumor"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoid Tumor"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Conditions: Functional Pancreatic Neuroendocrine Tumor;   Malignant Somatostatinoma;   Merkel Cell Carcinoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Carcinoid Tumor;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B;   Neuroendocrine Neoplasm;   Non-Functional Pancreatic Neuroendocrine Tumor;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Merkel Cell Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Adrenal Cortex Carcinoma;   Stage III Thyroid Gland Medullary Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IVA Thyroid Gland Medullary Carcinoma;   Stage IVB Thyroid Gland Medullary Carcinoma;   Stage IVC Thyroid Gland Medullary Carcinoma;   Thymic Carcinoid Tumor;   VIP-Producing Neuroendocrine Tumor;   Well Differentiated Adrenal Cortex Carcinoma;   Zollinger Ellison Syndrome
Interventions: Drug: Capecitabine;   Drug: Temozolomide;   Drug: Veliparib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
2 Not yet recruiting Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: regorafenib;   Other: laboratory biomarker analysis
3 Not yet recruiting A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Condition: Carcinoid Tumors
Interventions: Drug: Ramucirumab;   Drug: Somatostatin Analog
4 Recruiting Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Conditions: Carcinoid Tumor;   Metastatic Carcinoid Tumor;   Neuroendocrine Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Nintedanib;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
5 Recruiting A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Condition: Carcinoid Tumors
Interventions: Drug: Lanreotide;   Drug: Placebo (for sunitinib);   Drug: Sunitinib
6 Recruiting Personalized PRRT of Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor;   Carcinoma, Neuroendocrine
Intervention: Drug: 177Lu-Octreotate
7 Recruiting SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor
Intervention:
8 Not yet recruiting Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
Conditions: Neuroendocrine Tumors;   Gastrointestinal Neoplasms;   Carcinoid Tumors
Interventions: Drug: Lanreotide;   Device: Y-90 microspheres
9 Recruiting 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors
Intervention: Device: 68Ga-DOTATOC PET
10 Not yet recruiting 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Conditions: Neuroendocrine;   Neuroendocrine Tumor;   Neuroendocrine Cancer;   Neuroendocrine Carcinoma;   Carcinoid;   Carcinoid Tumor;   Islet Cell Tumor;   Apudoma
Intervention: Drug: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
11 Available Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy
Condition: Midgut Carcinoid Tumor
Intervention: Drug: 177Lu-DOTA0-Tyr3-Octreotate
12 Recruiting Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Conditions: Carcinoid Tumors;   Pancreatic NET
Intervention: Drug: Ibrutinib
13 Recruiting Natural History of Familial Carcinoid Tumor
Condition: Carcinoid
Intervention:
14 Recruiting Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Condition: Carcinoid Tumor
Intervention: Drug: Ziv-aflibercept
15 Recruiting Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors;   Neuroblastoma;   Medulloblastoma
Intervention: Drug: 68Ga-DOTATOC PET/CT
16 Recruiting Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Gastro Entero Pancreatic Neuroendocrine Tumors
Interventions: Drug: 28 GBq 177Lu-DOTATATE;   Drug: 22 GBq 177Lu-DOTATATE
17 Unknown  Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors
Condition: Carcinoid Neuroendocrine Cancer
Intervention:
18 Unknown  An Investigation of Small Intestinal Carcinoid Carcinoma in Families
Condition: Carcinoid Carcinoma
Intervention:
19 Available 18F-FDOPA PET in Neuroendocrine Tumours
Conditions: Thyroid Cancer, Medullary;   Carcinoid Tumor;   Pheochromocytoma;   Paraganglioma;   Insulinoma;   Neuroblastoma
Intervention: Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
20 Recruiting RegisterNET - A Registry for Neuroendocrine Tumors in the USA
Conditions: Neuroendocrine Tumor;   Carcinoid;   Neuroendocrine Carcinoma
Intervention: Device: NETest

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years